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Original Article
The Short-Term and Long-Term Effects of
Biofeedback-Assisted Relaxation Therapy in
Patients With Heart Failure: A Randomized
Control Study
Tsuey-Yuan Huang, PhD1, Debra K. Moser, PhD2, and
Shiow-Li Hwang, DNSc3
Abstract
Background: Relaxation techniques can reduce sympathetic nervous system activation and stress, potentially improving
heart failure patients’ physical and psychological outcomes.
Purpose: To examine the effects of biofeedback-assisted relaxation (BFAR) therapy in patients with heart failure.
Methods: A prospective randomized control study was conducted. Participants in the treatment group received BFAR
therapy, while participants in the control group received standard of care. Short-term outcomes were physical symptoms and
psychosocial variables measured at baseline and 3 months; long-term outcomes were cardiac events and mortality assessed
at 12 months.
Results: Fifty-two heart failure patients participated in the study: 23 (mean age 60.0 13.7 years; 60.9% male; 39.1% New
York Heart Association III/IV) in the treatment group and 29 (mean age 59.2 12.2 years; 72.4% male; 48.3% New York
Heart Association III/IV) in the control group. Short-term effects of BFAR on outcome variables were not significantly
different between treatment and control groups. However, longer event-free survival was found in the treatment group
compared with the control group (p¼ .019).
Conclusions/Implications for Practices: BFAR therapy is effective to improve cardiac event-free survival of heart failure
patients and can be applied to clinical setting.
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heart failure, biofeedback-assisted relaxation, short-term effect, long-term
Date received: 21 March 2016; revised: 30 September 2016; accepted: 16 October 2016
Introduction
Because developments in the management of heart dis-
ease have decreased mortality and thus the population is
living longer, heart failure incidence and prevalence are
expected to grow worldwide (Mozaffarian et al., 2015).
As a consequence, the global impact of this condition is
expected to dramatically intensify within the next 10
years (Mosterd & Hoes, 2007; Norton, Georgiopoulou,
Kalogeropoulos, & Butler, 2011). Patients with heart
failure experience debilitating physical symptoms, emo-
tional distress, impaired quality of life, frequent hospi-
talizations, and premature death (Atherton et al., 2012;
Ramani, Uber, & Mehra, 2010). To surmount the
increasing heart failure epidemic, effective and innova-
tive intervention strategies that improve outcomes for
patients with heart failure must be developed.
Previous studies have not focused on nonpharmaco-
logic intervention in heart failure management (Ramani
et al., 2010). The use of relaxation therapy to induce the
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relaxation response is one potentially beneficial nonphar-
macologic therapy in heart failure (Richardson, 2001;
Woltz et al., 2012). Herbert Benson, professor and car-
diologist of Harvard University, coined the term
Relaxation Response in the early 1970s and tried to des-
ignate a physical status, including reduced sympathetic
nervous system (SNS) tone, increased parasympathetic
activity, decreased metabolism, decreased heart rate
and blood pressure, and reduced oxygen consumption
(Benson & Klipper, 1976). The use of biofeedback is a
scientifically supported method of helping patients
achieve the relaxation response and could potentially
be used to lessen the negative sequelae of heart failure
(Moser, Dracup, Woo, & Stevenson, 1997; Yu, Lee, &
Woo, 2010).
The SNS initiates and sustains a series of intensive
neurotransmitter activation, which further leads to
marked vasoconstriction in heart failure. (Agarwal,
Briasoulis, & Messerli, 2013; Braith & Edwards, 2003).
Except for the disease-related physical manifestations or
incapability, heart failure patients are often involved in
different kinds of psychological distress, including feel-
ings of depression, anxiety, and loss of control (Dekker,
Peden, Lennie, Schooler, & Moser, 2009; Lee et al.,
2010). Both neurohumoral activation and psychological
consequences caused by heart failure can lead to
decreased quality of life, frequent heart failure hospital-
izations, and increased mortality. Biofeedback-assisted
relaxation (BFAR) therapy is an existing intervention
that has been shown in multiple previous studies to
both diminish psychological distress and improve phys-
ical symptoms and quality of life in diverse populations
(Evetovich, Conley, Todd, Rogers, & Stone, 2007;
Yu, Lee, & Woo, 2007; Yu, Lee, Woo, & Hui, 2007).
BFAR therapy includes three complementary, but dis-
tinct, strategies to improve outcomes. When done suc-
cessfully, BFAR (a) can decrease SNS activation, (b)
produce stress reduction, and (c) result in vasodilatation
(Moser et al., 1997; Yu et al., 2010). Through these syn-
ergistic effects, BFAR may have a powerful effect in
patients with heart failure, but the long-term effects of
this nonpharmacological intervention are unknown. The
specific aim of this study was to examine both the short-




A two-group, randomized prospective experimental
design was used in this study with assessments at baseline,
3, and 12 months. Three- and 12-month follow-ups were
chosen to assess the short- and long-term effects of the
intervention, respectively. To examine the effect of BFAR
and avoid the influence of angiotensin-converting-enzyme
inhibitor (ACEI) or angiotensin II receptor antagonist
(ARB) to outcomes, both within- and between-subject
comparisons were made to determine the effect of
BFAR therapy, with stratification to control for ACEI
or ARB use. Subjects were recruited using a stratified ran-
domization table so that half of participants had been
prescribed an ACEI or ARB. Patients were randomly
assigned to a BFAR therapy group and a usual care con-
trol group (Figure 1).
Sample and Data Collection Procedure
To be included in this BFAR study, patients (a) were
adults (older than 18 years) and (b) had a definite diag-
nosis of heart failure by a cardiologist. Patients with a
history of cerebral vascular accident, recent myocardial
infarction (within the preceding 6 months), a major
comorbid terminal illness, or receiving treatment such
as hemodialysis or concurrent cancer treatment, were
excluded. Patients with cognitive impairment or residing
in institutional settings were also excluded. Patients were
recruited from several medical centers located in southern
Taiwan. The approval to conduct the study was obtained
from the appropriate hospital institutional review boards
(97-010B and NTUH-REC 200710001R) and informed
consent was obtained from each patient. After identifying
patients with heart failure at the outpatient clinics, nurse
research assistants and cardiologists invited eligible sub-
jects to participate in the study. Patients completed the
questionnaires in the presence of nurse research assistants
who were available to answer any question. In some
cases, if necessary, the nurse research assistant read for
patients to help them to respond to questionnaire. In gen-
eral, it took the patients approximately 30 minutes to
complete the questionnaires.
Measurement via Validated Questionnaires
Physical symptoms and psychosocial variables (i.e.,
depression, anxiety, perceived control, perceived social
support, and health-related quality of life) were mea-
sured using the Modified Pulmonary Function Status
and Dyspnea Questionnaire (PFSDQ-M; Huang et al.,
2008a), Brief Symptom Inventory (BSI)-Depression &
Anxiety Subscale (Derogatis, 1993), Control Attitudes
Scale-Revised (Moser et al., 2009), Multidimensional
Scale of Social Support Scale (MSPSS; Bruwer,
Emsley, Kidd, Lochner, & Seedat, 2008), and
Minnesota Living with Heart Failure Questionnaire
(MLHFQ; Ho, Clochesy, Madigan, & Liu, 2007),
respectively. Demographic variables and New York
Heart Association (NYHA) functional class were
obtained by patient interview. Left ventricular ejection
fraction (LVEF) was obtained from the medical record.
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Physical symptoms of dyspnea and fatigue. The PFSDQ-M
was used to measure heart failure patients’ physical
symptoms in this study. The PFSDQ-M was developed
for measuring symptoms of patients with chronic pul-
monary obstructive disease in 1994 and modified in
1998 (Lareau, Meek, & Roos, 1998). Caroci then used
the PFSDQ-M to distinguish symptom differences
between patients with heart failure and chronic pulmon-
ary obstructive disease, and confirmed validity and reli-
ability in heart failure patients (Caroci Ade & Lareau,
2004). The PFDSQ-M is a 40-item questionnaire that
measures dyspnea and fatigue based on patients’ subject-
ive perception of the symptoms. It consists of questions
which assess the main components of the symptoms:
experience, frequency, and intensity of symptom.
The PFSDQ-M consists of general questions concerning
the patient’s experience of dyspnea and fatigue, the
frequency of symptom occurrence over the past month,
and the overall intensity of dyspnea and fatigue (i.e., on
most days, today, and with usual activity levels). Higher
scores indicate more severe physical symptoms induced
by heart failure. The Chinese version of the PFSDQ-M
has been validated and is reliable (Huang et al., 2008b).
In the current study, the Cronbach’s a of PFSDQ-M
was .92.
Depression and anxiety. The BSI Depression and Anxiety
Subscales (Derogatis, 2006) were used to measure heart
failure patients’ depression and anxiety levels in the
current study, and each contains six items (Derogatis,
1993). Patients rated their distress level related to a
given item on a scale from 0 to 4 (0¼ not at all and
4¼ extreme). The mean of these six items produces the
score. The score ranges from 0 to 4 for each subscale,
Assessed for eligibility (n= 101) 
Excluded (n=41) 
♦ Not meeting inclusion criteria (n=0) 
♦ Declined to participate (n=41) 
Analysed (n=23) 
♦ Excluded from analysis (give reasons) (n=0)
Lost to follow-up (n=2, for change service 
hospital) 
Discontinued intervention (for transportation 
issues)(n=4)
Allocated to treatment group (n=30) 
♦ Received allocated intervention (n=29)
♦ Did not receive allocated intervention (n=1,
for readmission within treatment period)
Lost to follow-up (n=1, for change service 
hospital) 
Discontinued intervention (n=0) 
Allocated tocontrol group (n=30) 
♦ Received allocated intervention (n=30)
♦ Did not receive allocated intervention (n=0)
Analysed (n=29) 
♦ Excluded from analysis (n=0)
Randomized (n=60) 
Figure 1. The flow diagrams of the participants through each stage of the study.
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and a higher score indicate higher levels of depression
and anxiety. The Cronbach’s a of the BSI-depression
and BSI-anxiety subscale was .82 and .73 in the current
study.
Perceived social support. MSPSS which contains 12 items is
a self-reported instrument used to measure social
support (Bruwer et al., 2008). The total score and sub-
scale scores for family, friends, and significant others
indicate the level of perceived support. The MSPSS
used a 7-point Likert scale where 1¼ very strongly dis-
agree and 7¼ very strongly agree; therefore, a higher
total score indicates more perceived support. The
Cronbach’s a of the MSPSS questionnaire in the current
study was .90.
Perceived control. The Control Attitudes Scale-Revised
(CAS-R; Moser et al., 2009) is an 8-item scale modified
from the original Cardiac Attitudes Index and Control
Attitudes Scale. The CAS-R developed by Moser et al.
(2009) measures the degree to which patients feel they
have control (and, conversely, a sense of helplessness)
related to their cardiac disease and can evaluate an indi-
vidual’s perspective of their ability to control their heart
condition Moser et al., 2009. Patients rate their level of
agreement with statements in the instrument on a 5-point
Likert scale, where a higher score indicates a higher level
of perceived control. The Cronbach’s a of the CAS-R in
the current study was .77 in the current study.
Health-related quality of life. The MLHFQ is a 21-item,
disease-specific measure of health-related quality of life
for patients with heart failure. Each item ranges from 0
to 5 and total scores range from 0 to 105. Higher
scores indicate a more negative perception of quality of
life. The MLHFQ has excellent psychometric properties,
and the Chinese version has been validated previously
(Ho et al., 2007).
Endpoint of cardiac event-free survival. Cardiac event-free
survival was defined as living with heart failure without
an emergency department visit for heart failure
exacerbation or hospital admission or death attributed
to cardiac events. Patient or family interview and med-
ical records were used to collect these data.
BFAR Intervention
The BFAR intervention in the current study was con-
ducted once a week for 6 weeks and consisted of skin
temperature BFAR. Sessions were individualized based
on the needs of the patient and included teaching, dem-
onstration, practice, and reinforcement of BFAR.
During each session, temperature sensors are attached,
and the display is placed where it can be seen by the
subject. Patients also hear an auditory signal that
changes pitch differentially as temperature increases
or decreases. In the first session, patients are given
instructions to assist them to increase their skin tem-
perature and they practice these for up to 20 minutes.
All remaining sessions begin with a review of the
practice diary and discussion of patients’ practice
experiences and any difficulties they had. Patients are
then attached to the biofeedback sensors and asked to
increase their skin temperature without coaching.
Sessions end with reinforcement to practice. The inter-
ventionist was a trained nursing specialist with expert-
ise in the care of patients with heart failure and
psychiatric counseling. All patients received the stand-
ard clinical care. Only patients in the treatment group
received the BFAR.
Statistics
In the associated results section and tables, categorical
data are presented as number (percentage) and continu-
ous data are presented as mean standard deviation. To
assess the effect of the intervention on short-term out-
comes, one-way analysis of covariance was used to com-
pare the adjusted posttest score (adjusted for pretest
score) between experimental and control groups. The
first event-free survival curves were depicted by the
Kaplan–Meier method, with the log rank test being
used to assess whether the treatment group (intervention
effect) was associated with longer time to first event
during 12-month follow-up. The difference in first
event-free survival between study groups was further
compared by a multivariate Cox proportional hazard
model with the adjustment of gender, age, LVEF,
NYHA functional class, and control attitudes scale
(CAS-R). All data analyses were conducted using SPSS
software version 22 (SPSS Inc., Chicago, IL).
Results
Baseline
A total of 40% of patients approached for enrollment
agreed to participate in the study. The low recruitment
rate was attributed to patients’ concerns about returning
for six classes, travel considerations, and burden for their
caregivers. Ultimately, 52 heart failure patients partici-
pated and completed the entire study, with 23 (mean age
60.0 13.7 years; 60.9% male; 39.1% NYHA III/IV) in
the BFAR treatment group and 29 (mean age 59.2 12.2
years; 72.4% male; 48.3% NYHA III/IV) in the control
group (Table 1). The distribution of sociodemographic
characteristics at baseline was homogeneous between the
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treatment and control groups (not statistically
significant).
There were no differences in the psychosocial vari-
ables at baseline between the study groups, except for
control attitudes scale (t¼ 2.65, p¼ .011). Heart failure
patients in the treatment group had higher levels of per-
ceived control at baseline than heart failure patients in
the control group (Table 1).
Short-Term Psychosocial Outcomes
There were no significant differences between psycho-
social variable outcomes measured at the 3-month
follow-up after controlling for baseline scores
(Table 2). Thus, there were no significant differences in
the treatment and control groups in overall scores of
dyspnea, fatigue, depression, anxiety, PSS, MLHFQ,
and CAS-R. The adjusted mean score of posttest and
their standard error and corresponding 95% confidence
intervals were shown at Table 3.
Long-Term Outcomes
The mean patient follow-up period was 294 days
(SD¼ 113 days). During this period, 18 patients
(34.6%) suffered a cardiac event. The incidence rate in
the treatment and control groups was 17.4% (4 out of
23) and 48.3% (14 out of 29), respectively.
The mean event-free survival time in the treatment
and control groups was 331 17 days and 264 23
days, respectively. The log-rank test from the Kaplan–
Meier analysis was statistically significant, 2(1)¼ 5.47,
p¼ .019, indicating that prognosis in the two groups was
different based on study group (Figure 2). In a further
multivariate Cox proportional hazard model controlling
for gender, age, LVEF, NYHA functional class, and








Age (years) 59.5 12.8 60.0 13.7 59.2 12.2 .836
Gender .552
Male 35 (67.3) 14 (60.9) 21 (72.4)
Female 17 (32.7) 9 (39.1) 8 (27.6)
Living arrangement .368
Live with loved one 47 (90.4) 22 (95.7) 25 (86.2)
Live alone 5 (9.6) 1 (4.3) 4 (13.8)
Marital status .513
Married 40 (76.9) 19 (82.6) 21 (72.4)
Not married 12 (23.1) 4 (17.4) 8 (27.6)
Ejection fraction (%) 44.4 16.1 48.5 18.7 41.1 13.2 .102
Preserved EF HF 31 (59.6) 15 (65.2) 16 (55.2) .573
NYHA .581
I/II 29 (55.8) 14 (60.9) 15 (51.7)
III/IV 23 (44.2) 9 (39.1) 14 (48.3)
Months since diagnosed HF 43.6 34.7 43.1 36.1 44.1 30.2 .621
Psychosocial variables at baseline
Dyspnea 2.09 2.54 1.59 2.19 2.48 2.75 .222
Fatigue 1.36 1.79 1.16 1.45 1.52 2.02 .486
Depression 0.83 0.87 0.78 0.99 0.88 0.77 .694
Anxiety 0.65 0.64 0.68 0.74 0.63 0.54 .812
Perceived social support 45.2 8.8 46.5 8.2 44.1 9.2 .352
MLHFQ 32.5 25.1 31.8 26.3 33.1 24.6 .854
Control Attitudes Scale-Revised 60.4 12.7 65.3 10.9 56.4 12.9 .011
Note. NYHA¼New York Heart Association functional classification; EF: ejection fraction; HF: heart failure; MLHFQ¼Minnesota Living with Heart Failure
Questionnaire. Categorical data were presented as N (%) and was compared using Fisher’s exact test. Continuous data were expressed as mean SD and
was compared using independent sample t-test.
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perceived control score from the CAS-R, the control
group had a higher risk of events when compared with
treatment group (adjusted hazard ratio¼ 4.42, 95% CI
of hazard ratio¼ 1.30 14.99, p¼ .017).
Discussion
In this study of a nonpharmacologic BFAR intervention
for management heart failure, we demonstrated that
event-free survival was significantly better in patients in
the treatment compared with the control group. There
was no short-term effect of the intervention seen at 3-
month follow-up as measured in the psychosocial or
symptom variables.
Although only a few investigators have examined the
effects of interventions similar to the BFAR intervention
tested in this study, most demonstrated that BFAR can
improve heart failure patients’ quality of life (Chang
et al., 2005; Yu et al., 2010) and psychological distress
(Yu et al., 2007). In these studies, outcomes were only
assessed within a time frame of 3 months after the inter-
vention. Our inability to demonstrate a short-term effect
of the intervention could be a result of too short a
follow-up period after the end of the intervention. It is
possible that testing at 6 or 9 months of psychosocial and
symptom variables would have demonstrated a signifi-
cant intervention effect. Our inability to find an effect on
quality of life, symptoms, and psychosocial variables
also may be related to an historical threat to internal
validity that occurred during our study.
The Typhoon Morakot landfall in southern Taiwan
affected around two thirds of our subjects during the
time period when posttest data were being collected.
Many participants in our study suffered from property
loss and unanticipated trauma from the disaster, which
may have impacted the short-term effects on heart failure
patients’ outcomes. Although our study was done with
scrupulous attention to protocol, the natural disaster and
resulting complications of this event were unavoidable.
A disaster such as this Typhoon likely overwhelmed
coping responses in the short-term.
Despite the lack of an intervention effect in the
short-term, a significant effect of the BFAR intervention
was found on event-free survival at the 12-month follow-
up. Our original hypothesis was that as a result of its
physical and psychological effects, BFAR could have a
clinically meaningful impact on rehospitalizations, sur-
vival, and quality of life. To produce a physical effect,
BFAR may be an effective adjunct to pharmacologic
therapy in the management of heart failure. Patients
may also receive psychological benefits from BFAR by
achieving stress reduction. Stress reduction may diminish
activation of SNS system (Woltz et al., 2012; Wu,
Corley, Lennie, & Moser, 2012). We speculate that
given the short follow-up after the intervention and the
acute overwhelming threat of the typhoon, it took longer
for the positive effects of the intervention to become
Table 3. Descriptive Statistics by Group of Adjusted Scores at 3 Months for All Short-Term Outcomes.
Treatment (n¼ 23) Control (n¼ 29)
Dependent variable Adjusted mean SE 95% CI Adjusted mean SE 95% CI
Dyspnea 1.71 0.42 0.87–2.55 1.82 0.34 1.13–2.51
Fatigue 1.33 0.31 0.72–1.95 1.07 0.27 0.53–1.61
Depression 0.56 0.13 0.30–0.83 0.88 0.12 0.64–1.12
Anxiety 0.38 0.12 0.15–0.62 0.53 0.10 0.32–0.73
PSS 47.98 1.62 44.73–51.23 46.77 1.40 43.95–49.58
MLHFQ 25.38 3.59 18.16–32.61 23.89 3.16 17.52–30.26
CAS-R 68.71 2.37 63.94–73.48 62.94 2.08 58.75–67.13
Note. The posttest score was adjusted by pretest score; SE¼ standard error; PSS¼ perceived social support; MLHFQ¼Minnesota Living with Heart Failure
Questionnaire; CAS-R¼Control Attitudes Scale-Revised.
Table 2. Summary Statistics for Comparison of 3-Month
Outcomes Between Patients in the Treatment and Control
Groups.
Dependent
variable SS df MS F p Z2 Power
Dyspnea 0.12 1 0.12 0.04 .846 .00 .05
Fatigue 0.86 1 0.86 0.42 .521 .01 .10
Depression 1.22 1 1.22 3.19 .081 .06 .42
Anxiety 0.24 1 0.24 0.84 .364 .02 .15
PSS 17.31 1 17.31 0.32 .575 .01 .09
MLHFQ 26.47 1 26.47 0.10 .756 .00 .06
CAS-R 355.91 1 355.91 3.12 .084 .06 .41
Note. SS¼ sum of square; df¼ degree of freedom; MS¼mean square;
Z¼ partial eta square; PSS¼ perceived social support; MLHFQ¼
Minnesota Living with Heart Failure Questionnaire; CAS-R¼Control
Attitudes Scale-Revised.
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apparent. Therefore, continuous enforcement and evalu-
ation when applying the BFAR to real clinical situation
may be necessary to assure this intervention has an
impact.
Given the effects of the intervention, there is still a gap
between clinical practice and the use of evidence from
empirical studies such as this one. BFAR takes time to
become familiar with and practice to exert an effect.
Within this context of the intervention, each patient
required about 350 minutes for the total BFAR therapy.
In the present health-care system, such an intervention
would not be affordable as a routine service. Pal,
Ganesh, Karthik, Nanda, and Pal (2013) found that
young medical students who practiced daily 1 hour for
6 weeks could improve their autonomic balance and pro-
mote cardiovascular health; heart failure patients even
need more time and practice to achieve the same effects.
Thus, further research to appropriately modify the tested
intervention is warranted.
Limitations
The study has a number of limitations. First, the gener-
alization of the results of this study is limited due to its
single center study. Second, any face-to-face encounter is
difficult to standardize. Intervention fidelity was
enhanced by training sessions with all interventionists
and consistence between them were confirmed before
real intervention session. However, the BFAR interven-
tion is complex, and there may have been some differ-
ences between interventionists. Finally, because the
BFAR require 6 weeks of engagement, patients who
were willing to receive the intervention could have
unique characteristics that made them more susceptible
to such intervention. Therefore, heart failure patients in
the treatment group had higher levels of perceived con-
trol at baseline than heart failure patients in the control
group even using randomization allocation in the study.
To control the treatment covariates, larger sample size or
different randomization method are needed for the
future study.
Conclusion
Our findings demonstrate that BFAR can improve the
end point of survival free of cardiac rehospitalization
and death in patients with heart failure. Although our
sample was small and unexpected internal validity issues
occurred, the positive effect of BFAR intervention
emerged.
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